Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2019
   Trial
2. Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.Haematologica · 2014
   Article
3. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.Haematologica · 2013
   Observational
4. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Hematology/oncology clinics of North America · 2011
   Review
5. Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group.Bone marrow transplantation · 2010
   Article
6. Hematopoietic stem cell transplantation: a global perspective.JAMA · 2010
   Article
7. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology.Haematologica · 2010
   Article
8. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.Bone marrow transplantation · 2009
   Article
9. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.Blood · 2008
   Article
10. Why are there regional differences in stem cell transplantation activity? An EBMT analysis.Bone marrow transplantation · 2008
    Article
11. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?Bone marrow transplantation · 2008
    Article
12. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products.Bone marrow transplantation · 2008
    Article
13. Has stem cell transplantation come of age in the treatment of sickle cell disease?Bone marrow transplantation · 2007
    Review
14. Do affluent societies have the only options for the best therapy?Leukemia · 2007
    Article
15. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors.Bone marrow transplantation · 2007
    Article

Corrections and comments

• Commented on by
  Do affluent societies have the only options for the best therapy?2007

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as